Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan

BACKGROUND: Clinical benefit of axitinib as a first line agent to treat patients with metastatic renal cell carcinoma (mRCC), or locally advanced renal cell carcinoma (RCC) have not been clearly demonstrated. The aim of this study was to evaluate the efficacy and safety of axitinib as first-line the...

Descripción completa

Detalles Bibliográficos
Autores principales: Koie, Takuya, Ohyama, Chikara, Yoneyama, Takahiro, Yamamoto, Hayato, Imai, Atsushi, Hatakeyama, Shingo, Hashimoto, Yasuhiro, Yoneyama, Tohru, Tobisawa, Yuki, Mori, Kazuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417199/
https://www.ncbi.nlm.nih.gov/pubmed/25887125
http://dx.doi.org/10.1186/s12894-015-0027-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417199/
https://www.ncbi.nlm.nih.gov/pubmed/25887125
http://dx.doi.org/10.1186/s12894-015-0027-4

Ejemplares similares